Pembrolizumab as first-line therapy in programmed death ligand 1–positive advanced lung cancer: Is it as effective as we think it is?

Daniel A. Goldstein, Usama Bilal, Vinay Prasad

Research output: Contribution to journal › Comment/debate › peer-review

4 Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab as first-line therapy in programmed death ligand 1–positive advanced lung cancer: Is it as effective as we think it is?'. Together they form a unique fingerprint.